Eolas partners with AstraZeneca in $145M deal; Sanaria raises $48.5M to fund malaria vaccine trials;

@FierceBiotech: FierceBiotech Radio on the cost of CAR-T, the future of Zoetis, and gentrification in Kendall Square. Listen | Follow @FierceBiotech

@JohnCFierce: Trending: Is Celgene killing the traditional biotech partnering formula? Editor's corner | Follow @JohnCFierce

@DamianFierce: Join us as we search for the Amar'e Stoudemire of immuno-oncology. FierceBiotech Radio  | Follow @DamianFierce

> Carlsbad, CA-based Eolas Therapeutics has struck a deal to partner with AstraZeneca ($AZN) on its Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. Eolas held back the details, but says the package is worth up to $145 million in milestones plus a potential royalty stream. Release

> Rockville, MD-based Sanaria has raised $48.5 million to develop a new malaria vaccine. The Government of the Republic of Equatorial Guinea is partnering with Marathon Oil Corporation, Noble Energy and AMPCO to sponsor the clinical development of Sanaria's PfSPZ Vaccine, with trials slated to run until 2018. Release

> Seattle-based Adaptive Biotechnologies is opening a New York office. Story

Medical Device News

@FierceMedDev: UPDATED: American Heart Association guidelines encourage use of stent retrievers to treat stroke. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Pay friends to quit smoking with Pfizer's new digital tool. FiercePharmaMarketing article | Follow @EmilyWFierce

> Feds sentence woman to 97 months in prison for fraudulently billing Medicare for wheelchairs. News

> ViewRay gets $50M in debt to back MRI-guided radiation therapy after IPO withdrawal. Story

Pharma News

@FiercePharma: UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. More | Follow @FiercePharma

@EricPFierce: Join us July 8 for a Twiiter chat on #sustainedrelease with BASF expert Thorsten Cech. Details are here. | Follow @EricPFierce

@CarlyHFierce: Not gonna lie, I purposely use the phrase "the Illinois pharma" every time I write about an Illinois pharma. | Follow @CarlyHFierce

> Biogen to build $1B plant, add 400 jobs in Switzerland. Story

> Sworn to end doc payments by 2016, GSK still shelled out $15M last year. More

Biotech Research News

> Researchers highlight a nuanced approach to flagging early Alzheimer's. Article

> Antibody 'cocktail' looks promising against deadly Marburg virus. News

> Salk investigators develop a new autophagy combo drug to starve tumors. More

> Dual cancer role for Daple attracts research team at UC San Diego. Article

> UCL team sees promise in mouse study of pancreatic tumor-targeting compound. Story

Diagnostics News

> Cinven snatches up Synlab for $1.96B to beef up in diagnostics. More

> Luxembourg's Eurofins rides JV diagnostics wave with Emory University deal. Editor's corner

> NIH provides Great Basin Scientific and BYU $5M+ to develop rapid test for CRE. Story

> Illumina unveils plans for new European HQ and science center. Item

> Qiagen launches Germany-based JV aimed at companion Dx. Article

Pharma Marketing News

> Feds demand $3.4B in damages, fines in Novartis kickback case. Story

> Latest Sunshine Act bombshell: $6.5B in doc-and-hospital payments last year. More

> House bill would force FDA to ease up on social media. Article

> Pay friends to quit smoking with Pfizer's new digital tool. Story

> Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.